Successful Control of Hypercalcemia with Sorafenib, Evocalcet, and Denosumab Combination Therapy for Recurrent Parathyroid Carcinoma

Parathyroid carcinoma (PC) is a rare type of endocrine cancer. Recurrence and metastasis are common after surgery, and refractory hypercalcemia often leads to a poor prognosis. However, there are currently no specific strategies for PC recurrence. We herein report a 61-year-old Japanese man with met...

Descripción completa

Detalles Bibliográficos
Autores principales: Makino, Hirofumi, Notsu, Masakazu, Asayama, Itsuko, Otani, Hazuki, Morita, Miwa, Yamamoto, Masahiro, Yamauchi, Mika, Nakao, Mika, Miyake, Hitomi, Araki, Asuka, Uchino, Shinya, Kanasaki, Keizo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751735/
https://www.ncbi.nlm.nih.gov/pubmed/35370235
http://dx.doi.org/10.2169/internalmedicine.9261-21
Descripción
Sumario:Parathyroid carcinoma (PC) is a rare type of endocrine cancer. Recurrence and metastasis are common after surgery, and refractory hypercalcemia often leads to a poor prognosis. However, there are currently no specific strategies for PC recurrence. We herein report a 61-year-old Japanese man with metastatic PC who was treated with sorafenib, a multikinase inhibitor. In this case, the serum calcium level was under control for 10 months after the initiation of sorafenib. This case suggests that combination therapy with sorafenib, evocalcet, and denosumab may be an alternative, stronger management option for refractory hypercalcemia in recurrent PC.

Ejemplares similares